|
GFM2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.37270000103385E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.15290000002322E-06 |
| Normal-vs-Stage2 |
7.387900E-02 |
| Normal-vs-Stage3 |
2.35050001684556E-09 |
| Normal-vs-Stage4 |
1.42840184125248E-11 |
| Stage1-vs-Stage2 |
9.082100E-02 |
| Stage1-vs-Stage3 |
2.938200E-02 |
| Stage1-vs-Stage4 |
5.193200E-04 |
| Stage2-vs-Stage3 |
5.440700E-03 |
| Stage2-vs-Stage4 |
4.646200E-04 |
| Stage3-vs-Stage4 |
2.250400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.52340001619211E-09 |
| Normal-vs-AfricanAmerican |
2.570700E-04 |
| Normal-vs-Asian |
1.25370000003677E-06 |
| Caucasian-vs-AfricanAmerican |
8.296200E-01 |
| Caucasian-vs-Asian |
8.753200E-01 |
| AfricanAmerican-vs-Asian |
7.618600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.26310000131613E-08 |
| Normal-vs-Female |
1.77340000018233E-07 |
| Male-vs-Female |
3.032400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.94909999998261E-06 |
| Normal-vs-Age(41-60Yrs) |
3.45079997909892E-09 |
| Normal-vs-Age(61-80Yrs) |
2.20369999999193E-05 |
| Normal-vs-Age(81-100Yrs) |
2.046200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.171820E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.382400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.441800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.694000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.663000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.126400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.954200E-02 |
| Classical-VS-Follicular |
1.198480E-02 |
| Classical-VS-Other |
7.638600E-01 |
| Classical-VS-Normal |
3.1779000542187E-09 |
| Tall-VS-Follicular |
1.956100E-04 |
| Tall-VS-Other |
3.801400E-01 |
| Tall-VS-Normal |
5.7033000544493E-09 |
| Follicular-VS-Other |
3.239800E-01 |
| Follicular-VS-Normal |
2.719900E-02 |
| Other-VS-Normal |
8.045000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.51039999963088E-07 |
| Normal-vs-N1 |
4.12090361834316E-11 |
| N0-vs-N1 |
1.102680E-03 |
|
|
